Statement on Bravecto

Nothing is more important to Merck Animal Health than the safety and efficacy of our products, and the health and well-being of animals. As you may be aware, a post on a social media site about Bravecto recently began circulating. As a responsible animal health company, we take every report seriously and investigate thoroughly. Please know we are working diligently to investigate the post and take all appropriate actions.
We have no information related to this post in our pharmacovigilance database, which means it has not been reported to Merck Animal Health. The poster identified herself as an acquaintance of the pet owner, and we are taking proactive measures to attempt to reach the poster, pet owner and the attending veterinarian to verify the information and get the facts. Among other things, we have reached out to the organization that hosts the Facebook page to try to make contact with the pet owner, and have contacted the individual who made the original post. At this point we have not received a response to our outreach.
In the meantime, we want to reiterate the safety of BRAVECTO.

• Merck Animal Health is confident in the safety of BRAVECTO, which has been established through a comprehensive clinical research program as well as through extensive post-marketing surveillance.
• BRAVECTO has been prescribed to millions of dogs around the world, and reports of adverse events have been extremely low and consistent with the product label.
• Regulatory agencies around the world have consistently affirmed that BRAVECTO is safe for use as indicated in its label.

Again, our commitment is to the health and well-being of pets, and addressing this situation is a priority.
IMPORTANT SAFETY INFORMATION: The most common adverse reactions recorded in clinical trials were vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. Bravecto has not been shown to be effective for 12-weeks’ duration in puppies less than 6 months of age. Bravecto is not effective against lone star ticks beyond 8 weeks after dosing. For full prescribing information, click here.